Single-arm phase II study of aggressive local therapy in combination with systemic chemotherapy for stageIV non-small cell carcinoma not harboring EGFR mutation and ALK fusion gene with oligometastases
Not Applicable
- Conditions
- on-small Cell Lung Cancer
- Registration Number
- JPRN-UMIN000022431
- Lead Sponsor
- Thoracic Oncology Research Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 19
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with pleural effusion, cardiac effusion, pleural dissemination, peritoneal dissemination, and/or ascites 2) Patients who are ineligible to treat with thoracic radiotherapy due to interstitial pneumonitis and/or severe COPD
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Two-year survival rate
- Secondary Outcome Measures
Name Time Method -Overall Survival -Progression Free Survival -Adverse Event